DK1162969T3 - Anvendelse af dipeptidylpeptidase IV inhibitorer til forbedring af frugtbarheden - Google Patents

Anvendelse af dipeptidylpeptidase IV inhibitorer til forbedring af frugtbarheden

Info

Publication number
DK1162969T3
DK1162969T3 DK00911186T DK00911186T DK1162969T3 DK 1162969 T3 DK1162969 T3 DK 1162969T3 DK 00911186 T DK00911186 T DK 00911186T DK 00911186 T DK00911186 T DK 00911186T DK 1162969 T3 DK1162969 T3 DK 1162969T3
Authority
DK
Denmark
Prior art keywords
inhibitors
dipeptidyl peptidase
improve fertility
fertility
improve
Prior art date
Application number
DK00911186T
Other languages
Danish (da)
English (en)
Inventor
Pierre Broqua
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Application granted granted Critical
Publication of DK1162969T3 publication Critical patent/DK1162969T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK00911186T 1999-03-23 2000-03-21 Anvendelse af dipeptidylpeptidase IV inhibitorer til forbedring af frugtbarheden DK1162969T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9906714.2A GB9906714D0 (en) 1999-03-23 1999-03-23 Compositions for improving fertility

Publications (1)

Publication Number Publication Date
DK1162969T3 true DK1162969T3 (da) 2006-09-18

Family

ID=10850229

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00911186T DK1162969T3 (da) 1999-03-23 2000-03-21 Anvendelse af dipeptidylpeptidase IV inhibitorer til forbedring af frugtbarheden

Country Status (29)

Country Link
US (1) US7115650B1 (ko)
EP (1) EP1162969B1 (ko)
JP (1) JP2002539243A (ko)
KR (1) KR100689951B1 (ko)
CN (1) CN1196483C (ko)
AR (1) AR023129A1 (ko)
AT (1) ATE328594T1 (ko)
AU (1) AU765912B2 (ko)
CA (1) CA2366911C (ko)
CZ (1) CZ20013410A3 (ko)
DE (1) DE60028552T2 (ko)
DK (1) DK1162969T3 (ko)
ES (1) ES2265918T3 (ko)
GB (1) GB9906714D0 (ko)
HK (1) HK1046647B (ko)
HU (1) HUP0200410A3 (ko)
IL (1) IL145569A0 (ko)
MX (1) MXPA01009612A (ko)
MY (1) MY135683A (ko)
NO (1) NO20014607L (ko)
NZ (1) NZ514449A (ko)
PL (1) PL195779B1 (ko)
PT (1) PT1162969E (ko)
RU (1) RU2246944C2 (ko)
TR (1) TR200102647T2 (ko)
TW (1) TWI244920B (ko)
UA (1) UA77644C2 (ko)
WO (1) WO2000056296A2 (ko)
ZA (1) ZA200108083B (ko)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979697B1 (en) 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
GB9928330D0 (en) * 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6512120B1 (en) 2001-03-12 2003-01-28 Ortho Mcneil Pharmaceutical, Inc. Methods for the synthesis of densely functionalized pyrrolidine intermediates
GB0109146D0 (en) * 2001-04-11 2001-05-30 Ferring Bv Treatment of type 2 diabetes
HUP0400321A2 (hu) 2001-06-27 2004-08-30 Smithkline Beecham Corp. Fluorpirrolidin-származékok mint dipeptidil-dipeptidáz inhibitorok és ezeket tartalmazó gyógyszerkészítmények
DE60223920T2 (de) 2001-06-27 2008-11-13 Smithkline Beecham Corp. Pyrrolidine als dipeptidyl-peptidase-inhibitoren
US7183290B2 (en) 2001-06-27 2007-02-27 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
EP1338595B1 (en) 2002-02-25 2006-05-03 Eisai Co., Ltd. Xanthine derivatives as DPP-IV inhibitors
US6710040B1 (en) 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
EP1514552A4 (en) 2002-06-06 2008-04-02 Eisai R&D Man Co Ltd NEW MILED IMIDAZOLE DERIVATIVE
WO2005026114A1 (en) * 2003-09-17 2005-03-24 Pfizer Inc. Hiv protease inhibitors, compositions containing the same and their pharmaceutical uses
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
CA2622472C (en) 2005-09-14 2013-11-19 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US8247438B2 (en) 2008-02-27 2012-08-21 Neuropill, Inc. Methods for treating schizophrenia
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
JP2013523819A (ja) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ, インコーポレイテッド Gpr119レセプターのモジュレーターおよびそれに関連する障害の処置
KR101871011B1 (ko) 2010-09-22 2018-06-25 아레나 파마슈티칼스, 인크. Gpr119 수용체의 조절제 및 그와 관련된 장애의 치료
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CA2979033A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11583516B2 (en) * 2016-09-07 2023-02-21 Trustees Of Tufts College Dash inhibitors, and uses related thereto
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016339A1 (en) 1990-04-14 1991-10-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type iv
CA2121369C (en) * 1991-10-22 2003-04-29 William W. Bachovchin Inhibitors of dipeptidyl-aminopeptidase type iv
IL111785A0 (en) * 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US5952301A (en) 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function

Also Published As

Publication number Publication date
PL350797A1 (en) 2003-02-10
DE60028552D1 (de) 2006-07-20
HUP0200410A2 (en) 2002-08-28
PL195779B1 (pl) 2007-10-31
HUP0200410A3 (en) 2002-09-30
RU2246944C2 (ru) 2005-02-27
TR200102647T2 (tr) 2002-01-21
CA2366911A1 (en) 2000-09-28
KR20010108388A (ko) 2001-12-07
CA2366911C (en) 2010-01-19
NZ514449A (en) 2002-11-26
ZA200108083B (en) 2002-11-27
CN1352557A (zh) 2002-06-05
WO2000056296A2 (en) 2000-09-28
MXPA01009612A (es) 2002-07-02
NO20014607L (no) 2001-11-20
HK1046647A1 (en) 2003-01-24
EP1162969A2 (en) 2001-12-19
WO2000056296A3 (en) 2001-01-25
IL145569A0 (en) 2002-06-30
UA77644C2 (en) 2007-01-15
KR100689951B1 (ko) 2007-03-08
NO20014607D0 (no) 2001-09-21
AU765912B2 (en) 2003-10-02
AU3317700A (en) 2000-10-09
CZ20013410A3 (cs) 2002-04-17
MY135683A (en) 2008-06-30
ES2265918T3 (es) 2007-03-01
US7115650B1 (en) 2006-10-03
CN1196483C (zh) 2005-04-13
ATE328594T1 (de) 2006-06-15
AR023129A1 (es) 2002-09-04
DE60028552T2 (de) 2007-06-28
HK1046647B (zh) 2005-09-30
GB9906714D0 (en) 1999-05-19
EP1162969B1 (en) 2006-06-07
TWI244920B (en) 2005-12-11
PT1162969E (pt) 2006-10-31
JP2002539243A (ja) 2002-11-19

Similar Documents

Publication Publication Date Title
DK1162969T3 (da) Anvendelse af dipeptidylpeptidase IV inhibitorer til forbedring af frugtbarheden
NO20025079D0 (no) Inhibitorer av dipeptidylpeptidase IV
NO20024295D0 (no) Cyclopropyl-kondenserte pyrrolidin-baserte inhibitorer av dipeptidyl peptidase IV og fremgangsmåte
MA28578B1 (fr) Dérivés de proline et leur utilisation comme inhibiteurs de la dipeptidyl-peptidase IV
NO20006483L (no) Forbindelser av ustabile dipeptidyl peptidase IV-inhibitorer
PL370220A1 (en) Inhibitors of dipeptidyl peptidase iv
AU2002360732A8 (en) Change inhibitors of dipeptidyl peptidase iv
ATE256127T1 (de) Betacarbolinderivate als phosphodiesterase- inhibitoren
NO20041709L (no) N-substituerte pyrrolidinderivater som dipeptidyl peptidase IV inhibitorer
CY2200151T2 (el) Χρηση αναστολεων διπεπτιδυλοπεπτιδασης για ρυθμιση του μεταβολισμου της γλυκοζης
EP1228061A4 (en) DIPEPTIDYL PEPTIDASE IV INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF
NO20026038D0 (no) Kombinasjoner av dipeptidylpeptidase IV inhibitorer og andre antidiabetiskemidler for behandlingen av diabetes mellitus
DE60329282D1 (de) Cyano-pyrrolidine als DPP-IV Inhibitoren
PL370149A1 (en) Novel dipeptidyl peptidase iv (dp-iv) inhibitors as anti-diabetic agents
DE60002193D1 (de) Metalloprotease inhibitoren
ATE437862T1 (de) Pyrimidin-5-onderivate als ldl-pla2 inhibitoren
DE60106252D1 (de) Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren
DE50107316D1 (de) Neue substituierte imidazotriazinone als pde ii-inhibitoren
NO20022125D0 (no) Pyrrolderivater som inhibitorer for fosfodiesterase VII
NO20014243L (no) Dihetero-substituerte metalloproteaseinhibitorer
AU2001263786A1 (en) Purified proenzyme of dipeptidyl peptidase i (pro-dppi)
ID28566A (id) Alat untuk menginjeksi spesi semen
AU2002216425A1 (en) Dipeptidyl peptidase IV inhibitor
ITPE20000005A0 (it) Cubiera riutilizzabile per provini di calcestruzzo
ZA200403090B (en) N-substituted pyrrolidin derivatives as dipeptidyl peptidase IV inhibitors.